IS SWITCHING FROM IV TO SC ABATACEPT THERAPY SUSTAINABLE IN THE REAL WORLD? 1-YEAR ANALYSIS OF THE PROSPECTIVE, INTERNATIONAL ACTION STUDY

被引：0
|
作者：
Alten, R. [1 ]
Nuesslein, H. [2 ]
Galeazzi, M. [3 ]
Lorenz, H. M. [4 ]
Mariette, X. [5 ]
Cantagrel, A. [6 ]
Chartier, M. [7 ]
Elbez, Y. [8 ]
Rauch, C. [9 ]
Le Bars, M. [10 ]
机构：
[1] Schlosspk Klin Univ Med, Berlin, Germany
[2] Univ Erlangen Nurnberg, Nurnberg, Germany
[3] Univ Siena, Siena, Italy
[4] Univ Hosp, Heidelberg, Germany
[5] Univ Paris Sud, Paris, France
[6] Hop Purpan, Toulouse, France
[7] Chiltern Int, Neuilly, France
[8] Excelya, Boulogne, France
[9] Bristol Myers Squibb, Munich, Germany
[10] Bristol Myers Squibb, Rueil Malmaison, France
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2016年 / 75卷
关键词：
SUBCUTANEOUS FORMULATION;
D O I：
10.1136/annrheumdis-2016-eular.1515
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
AB0371
引用
收藏
页码：1030 / 1031
页数：2
相关论文
共 50 条
  • [1] In Real-World Clinical Practice, Patients Switching from IV to SC Abatacept Maintain Clinical Efficacy after Switch
    Alten, Rieke
    Lorenz, H. M.
    Mariette, X.
    Nuesslein, H.
    Galeazzi, M.
    Navarro, F.
    Chartier, M.
    Heitzmann, J.
    Rauch, C.
    Le Bars, M.
    ARTHRITIS & RHEUMATOLOGY, 2017, 69
  • [2] ADHERENCE TO THE RECOMMENDED DOSING REGIMEN OF ABATACEPT: RESULTS FROM THE INTERNATIONAL, REAL-WORLD ACTION STUDY
    Nuesslein, H.
    Alten, R.
    Galeazzi, M.
    Lorenz, H. M.
    Boumpas, D.
    Nurmohamed, M. T.
    Bensen, W. G.
    Burmester, G. R.
    Peter, H. -H.
    Rainer, F.
    Pavelka, K.
    Chartier, M.
    Poncet, C.
    Rauch, C.
    Le Bars, M.
    ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 : 453 - 453
  • [3] Adherence to the recommended dosing regimen of abatacept: results from the international, real-world ACTION study
    Nuesslein, H.
    Alten, R.
    Galeazzi, M.
    Lorenz, H.
    Boumpas, D.
    Nurmohamed, M.
    Bensen, W.
    Burmester, G.
    Peter, H.
    Rainer, F.
    Pavelak, K.
    Chartier, M.
    Poncet, C.
    Rauch, C.
    LeBars, M.
    ZEITSCHRIFT FUR RHEUMATOLOGIE, 2013, 72 : 102 - 103
  • [4] SWITCHING INFLIXIMAB TO SUBCUTANEOUS FROM INTRAVENOUS THERAPY (SWIMSUIT) - A PROSPECTIVE, REAL-WORLD PHASE IV INTERVENTIONAL STUDY
    Rahmany, Sohail
    Young, David
    Moyses, Helen
    Gonclaves, Joao
    Latter, Sue
    Cummings, Fraser
    GUT, 2023, 72 (SUPPL_2) : A92 - A93
  • [5] TWO-YEAR RETENTION AND EFFECTIVENESS OF IV ABATACEPT IN REAL-LIFE SETTING: RESULTS FROM THE ACTION STUDY
    Nuesslein, H.
    Alten, R.
    Galeazzi, M.
    Lorenz, H. -M.
    Nurmohamed, M.
    Bensen, W.
    Burmester, G. -R.
    Peter, H. -H.
    Pavelka, K.
    Chartier, M.
    Poncet, C.
    Rauch, C.
    Le Bars, M.
    ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 : 500 - 501
  • [6] SWITCHING INFLIXIMAB TO SUBCUTANEOUS FROM INTRAVENOUS THERAPY (SWIMSUIT) - A PROSPECTIVE, REAL-WORLD, SINGLE CENTRE, PHASE IV INTERVENTIONAL STUDY
    Rahmany, Sohail
    Young, David
    Moyses, Helen
    Goncalves, Joao
    Latter, Sue
    Cummings, Fraser
    GASTROENTEROLOGY, 2023, 164 (06) : S1121 - S1121
  • [7] Prognostic Factors for IV Abatacept Retention in Patients Who Have Received at Least One Prior Biologic Agent: 2-Year Results from a Prospective, International, Real-World Study
    Nuesslein, H.
    Alten, R.
    Galeazzi, M.
    Lorenz, H. M.
    Nurmohamed, M. T.
    Bensen, W. G.
    Burmester, Gerd
    Peter, H-H
    Peichl, P.
    Pavelka, K.
    Chartier, M.
    Poncet, C.
    Rauch, C.
    Le Bars, M.
    ARTHRITIS & RHEUMATOLOGY, 2014, 66 : S1087 - S1088
  • [8] UP TO 5-YEAR RETENTION OF ABATACEPT IN BELGIAN PATIENTS WITH MODERATE-TO-SEVERE RA: PROSPECTIVE DATA FROM THE REAL-WORLD ACTION STUDY
    Westhovens, R.
    Connolly, S. E.
    Margaux, J.
    Vanden Berghe, M.
    Maertens, M.
    Van den Berghe, M.
    Elbez, Y.
    Chartier, M.
    Baeke, F.
    Robert, S.
    Malaise, M.
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 1393 - 1393
  • [9] ACPA POSITIVITY DETERMINES REMISSION IN PATIENTS WITH RA TREATED WITH IV AND SC ABATACEPT: A POST HOC ANALYSIS OF THE REAL-WORLD OBSERVATIONAL ACTION AND ASCORE STUDIES
    Alten, R.
    Rauch, C.
    Chartier, M.
    Nurmohamed, M. T.
    Connolly, S.
    Buch, M. H.
    Peichl, P.
    Mariette, X.
    Patel, Y.
    Marsal, S.
    Caporali, R.
    Griffiths, H.
    Sanmarti, R.
    Bannert, B.
    Elbez, Y.
    Lozenski, K.
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 276 - 277
  • [10] Switching infliximab to subcutaneous from intravenous therapy (SWIMSUIT) - A prospective, real-world, single centre, phase IV interventional study.
    Rahmany, S.
    Young, D.
    Moyses, H.
    Gonclaves, J.
    Latter, S.
    Cummings, F.
    JOURNAL OF CROHNS & COLITIS, 2023, 17 : 522 - 522
12345